- Home
- LGL vs IGC Comparison
LGL vs IGC Comparison
Compare LGL & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGL
- IGC
- Stock Information
- Founded
- LGL 1917
- IGC 2005
- Country
- LGL United States
- IGC United States
- Employees
- LGL N/A
- IGC N/A
- Industry
- LGL Industrial Machinery/Components
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- LGL Technology
- IGC Health Care
- Exchange
- LGL Nasdaq
- IGC Nasdaq
- Market Cap
- LGL 34.1M
- IGC 39.8M
- IPO Year
- LGL N/A
- IGC N/A
- Fundamental
- Price
- LGL $6.50
- IGC $0.41
- Analyst Decision
- LGL
- IGC Strong Buy
- Analyst Count
- LGL 0
- IGC 2
- Target Price
- LGL N/A
- IGC $4.00
- AVG Volume (30 Days)
- LGL 3.9K
- IGC 1.4M
- Earning Date
- LGL 11-12-2025
- IGC 11-11-2025
- Dividend Yield
- LGL N/A
- IGC N/A
- EPS Growth
- LGL N/A
- IGC N/A
- EPS
- LGL 0.04
- IGC N/A
- Revenue
- LGL $4,178,000.00
- IGC $1,327,000.00
- Revenue This Year
- LGL N/A
- IGC $15.26
- Revenue Next Year
- LGL N/A
- IGC $3.41
- P/E Ratio
- LGL $161.08
- IGC N/A
- Revenue Growth
- LGL 6.34
- IGC 24.95
- 52 Week Low
- LGL $5.39
- IGC $0.25
- 52 Week High
- LGL $9.74
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- LGL 42.55
- IGC 52.22
- Support Level
- LGL $6.52
- IGC $0.38
- Resistance Level
- LGL $6.82
- IGC $0.47
- Average True Range (ATR)
- LGL 0.14
- IGC 0.04
- MACD
- LGL 0.02
- IGC -0.00
- Stochastic Oscillator
- LGL 34.69
- IGC 32.79
About LGL LGL Group Inc. (The)
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.